Adial Pharmaceuticals reports Q3 net loss of $1.8 million
Adial Pharmaceuticals reported a Q3 2025 net loss of $1.8 million, down from $2.2 million in Q3 2024. R&D expenses decreased by 50%, while general and administrative expenses rose by 5%. Cash reserves fell to $4.6 million, expected to fund operations until Q2 2026. Business updates include a provisional patent for AD04 and progress toward FDA approval.
Adial Pharmaceuticals reported a net loss of $1.8 million for the third quarter of 2025, compared to a net loss of $2.2 million for the same period in 2024. Research and development expenses decreased by approximately $0.5 million, or 50%, due to lower clinical activity. General and administrative expenses increased by about $0.1 million, or 5%, mainly due to the timing of the company’s annual meeting. Cash and cash equivalents were $4.6 million as of September 30, 2025, down from $5.9 million as of June 30, 2025. The company expects its current cash position to fund operations into the second quarter of 2026. Business developments included the filing of an updated provisional patent application for AD04, its lead investigational drug for Alcohol Use Disorder, and progress toward FDA approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-110385), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
